ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2012

Abstract Number: 1902

What Factors Are Associated with Target Serum Urate Concentrations in Patients with Gout?

Nicola Dalbeth1, Meaghan House2, Anne Horne2, Keith J. Petrie3, Fiona M. McQueen4 and William Taylor5, 1Medicine, University of Auckland, Auckland, New Zealand, 2Department of Medicine, University of Auckland, Auckland, New Zealand, 3University of Auckland, Auckland, New Zealand, 4Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand, 5University of Otago, Wellington, New Zealand

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2012

Keywords: Gout and uric acid

Session Information

Title: Metabolic and Crystal Arthropathies

Session Type: Abstract Submissions (ACR)

Background/Purpose: Long term serum urate (SU) lowering to a target of <6mg/dL is recommended for effective gout management.  However, many studies have reported low achievement of SU targets.  The aim of this study was to examine the clinical and psychological factors associated with SU targets in patients with gout. 

Methods: Patients with gout for <10 years were recruited from primary and secondary care settings.  SU target was defined as SU concentration <6mg/dL at the time of the study visit. Both clinical and psychological factors associated with SU target were analysed.  The relationship between SU target and measures of gout activity including flare frequency in the preceding three months was also analysed. 

Results: Of the 273 patients enrolled into the study, 89 (32.6%) had SU concentration <6mg/dL.  Urate-lowering therapy (ULT) use was strongly associated with SU target (p<0.001).  In those patients prescribed ULT (n=181), allopurinol dose, patient confidence to keep SU under control, female sex, and ethnicity were independently associated with SU target (Table).  Other patient psychological factors and health-related behaviours, including adherence scores, were not independently associated with SU target in those taking ULT.  Creatinine clearance, diuretic use, age, and body mass index were not associated with SU target.  Patients at SU target reported lower gout flare frequency, compared with those not at target (p=0.03).

Conclusion: ULT prescription and dosing are key modifiable factors associated with achieving SU target.  These data support interventions focusing on improved use of ULT to optimise outcomes in patients with gout. 

Table. Forward stepwise logistic regression analysis of factors associated with SU target in those taking ULT. Model included all factors with p<0.15 between groups in univariate analysis.

Variable

OR

95% CI

p

Model

Female sex

4.34

1.65-11.44

0.003

Adjusted R2=0.35,

p<0.001

Māori or Pacific ethnicity

0.19

0.07-0.52

0.001

Allopurinol dose (per every 100mg/day)

2.22

1.43-3.44

<0.001

Confidence to keep serum urate under control (per every point on 0-10 Likert scale)

1.025

1.007-1.044

0.006

Excluded from model: adherence score, secondary care treatment, age, confidence to have blood tests at recommended frequency, confidence to take gout medications regularly, Brief Illness Perception Questionnaire (BIPQ) treatment control score, BIPQ understanding score.

 


Disclosure:

N. Dalbeth,
None;

M. House,
None;

A. Horne,
None;

K. J. Petrie,
None;

F. M. McQueen,
None;

W. Taylor,
None.

ACR Meeting Abstracts - https://acrabstracts.org/abstract/what-factors-are-associated-with-target-serum-urate-concentrations-in-patients-with-gout/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology